NASDAQ · ABEO
Abeona Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ABEO: Nov 11, 2026
Abeona Therapeutics Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.1.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $0.03 | $-0.25 | 5 |
| Dec 2026 | $-0.09 | $0.09 | $-0.24 | 5 |
| Mar 2027 | $-0.02 | $0.13 | $-0.20 | 3 |
| Jun 2027 | $0.04 | $0.17 | $-0.16 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · The Motley Fool · NASDAQ.com- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- MarketBeat · Sep 22, 6:02 PM EDTAbeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. WainwrightAbeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. Madhav Vasanthavada, Abeona’s se
- MarketBeat · Sep 22, 4:02 AM EDTAbeona Expands ZEVASKYN Network as RDEB Launch Gains MomentumAbeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that th
- RTTNews · Sep 18, 8:01 AM EDTAbeona Therapeutics (ABEO) Highlights FDA Approval Of FAYUVI Gene Therapy For MPS IIIA(RTTNews) – Abeona Therapeutics Inc. (ABEO) congratulated Ultragenyx Pharmaceutical Inc. (RARE) on the U.S. FDA approval of FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of Sanfilippo syndrome type A (MPS IIIA).
- RTTNews · Sep 16, 3:11 PM EDTAbeona Activates Eighth U.S. Testing Site For ZEVASKYN In Epidermolysis Bullosa; Stock Down(RTTNews) – Abeona Therapeutics Inc. (ABEO), a commercial-stage biopharmaceutical company, announced on Wednesday the activation of an eighth clinical testing site at the University of Florida Health (UF Health) for ZEVASKYN in treating recessive dystrophic epidermolysis bullosa.
- The Motley Fool · Aug 20, 10:43 AM EDTAbeona (ABEO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 13, 11:25 AM EDTAbeona Therapeutics Swings To Q2 Net Loss; Shares Plunge(RTTNews) – Abeona Therapeutics Inc. (ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies, reported financial results for the second quarter reflecting a swing to a net loss compared to profit a year ago, with the year-ago results largely driven
- MarketBeat · Aug 13, 10:05 AM EDTAbeona Therapeutics Q2 Earnings Call HighlightsAbeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition. The company recorded net ZEVASKYN revenue of $1
- The Motley Fool · May 13, 5:01 PM EDTAbeona (ABEO) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 13, 10:07 AM EDTAbeona Therapeutics Q1 Earnings Call HighlightsAbeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company’s
- The Motley Fool · Mar 17, 9:51 AM EDTAbeona (ABEO) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- NASDAQ.com · Mar 16, 4:00 PM EDTPre-Market Earnings Report for March 17, 2026 : ESLT, GDS, TME, ATAT, CAAP, ASO, TSAT, HUYA, ABEO, STIM, ICCM, PSQHThe following companies are expected to report earnings prior to market open on 03/17/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Elbit Systems Ltd. (ESLT)is reporting for the quarter ending December 31, 2025. The aerospace and defense company
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Abeona Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.